A Randomised, Open Label Switch Study Comparing Darunavir/Ritonavir 400mg/100mg Daily With Lopinavir/Ritonavir 800mg/200mg Daily, in HIV-positive Participants
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Darunavir (Primary) ; Lopinavir; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2018 Primary endpoint (Number of participants with undetectable HIV-1 RNA levels) has been met, according to the results presented at the 22nd International AIDS Conference
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference
- 21 Jun 2018 Status changed from recruiting to completed.